New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
05:55 EDTBSX, BSX, BSX, BSX, RNST, RNST, RNST, RNST, HBHC, HBHC, HBHC, HBHC, IBKC, IBKC, IBKC, IBKC, HOMB, HOMB, HOMB, HOMB, SFNC, SFNC, SFNC, SFNC, OZRK, OZRK, OZRK, OZRK, PNFP, PNFP, PNFP, PNFP, UCBI, UCBI, UCBI, UCBIStephens to host a field trip
Bank Field Trip travels through Memphis, New Orleans, Little Rock, Nashville and Atlanta on February 19-22.
News For BSX;RNST;HBHC;IBKC;HOMB;SFNC;OZRK;PNFP;UCBI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
10:00 EDTSFNCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:53 EDTSFNCSimmons First National initiated with a Buy at Sterne Agee
Subscribe for More Information
November 20, 2014
07:49 EDTHBHCHancock Holding co-CEO didn't leave due to fundamental change, says SunTrust
After speaking with Hancock's new CEO, SunTurst says it is reassured that co-CEO Carl Chaney did not decide to leave the company due to a change in its fundamental outlook. The firm says that the company's strategy is unchanged, and it keeps a $40 price target and Buy rating on the shares.
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
November 19, 2014
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
06:30 EDTBSXJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
18:41 EDTSFNCSimmons First National shareholders approve mergers
Subscribe for More Information
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
07:37 EDTBSXStifel to hold a conference
Subscribe for More Information
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information
November 14, 2014
12:53 EDTBSXOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
08:41 EDTHBHCHancock Holding announces retirement of CEO Carl Chaney
Subscribe for More Information
November 13, 2014
17:10 EDTBSXBoston Scientific S-ICD System receives favorable coding, payment designations
Subscribe for More Information
November 12, 2014
07:27 EDTBSXNorth American Spine Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use